{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:15:49Z","timestamp":1740104149276,"version":"3.37.3"},"reference-count":28,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To observe the efficacy and safety of telbivudine on mother\u2010infant blockade in pregnant women with hepatitis B virus (HBV) DNA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 141 pregnant women between 24 and 28 weeks of gestation and chronic HBV carriers with HBV DNA \u226510<jats:sup>6<\/jats:sup>\u2009copies\/mL were enrolled, 105 in the treatment group and 36 in the control group. The treatment group was given telbivudine 600\u2009mg\/d oral, and the control group did not use antiviral drugs. Hepatitis B immunoglobulin 200\u2009IU intramuscular injection and hepatitis B vaccine (HBVac) 10\u2009\u03bcg subcutaneous injection were given to the infants in both groups within 12\u2009hours after birth, and 10\u2009\u03bcg of HBVac was subcutaneously injected when the infants were 1\u2010month and 6\u2010month old. Safety endpoints including HBV DNA quantification, liver function, CK were observed before treatment, 4 weeks after treatment, before delivery, and 24 weeks after delivery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was no difference in HBV DNA levels between the two groups before treatment and 6 months after delivery (<jats:italic>P<\/jats:italic>\u2009&gt;\u2009.05). The HBV DNA level in the treatment group was significantly lower than that in the control group before delivery (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05). Between the two groups, the HBV positive rate was statistically different between the two groups (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05), and the difference of serum HBsAg of infants had statistical significance (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05), but the safety of the telbivudine group was not significantly different from that of the control group (<jats:italic>P<\/jats:italic>\u2009&gt;\u2009.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The application of telbivudine antiviral therapy in the middle and late stage of pregnancy of HBV high\u2010load pregnant women can significantly reduce the HBV DNA level before delivery, reduce the mother\u2010to\u2010child transmission rate of HBV, and have excellent security.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jmv.25566","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T09:34:15Z","timestamp":1565343255000},"page":"2153-2157","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of telbivudine to prevent mother\u2010to\u2010child transmission of hepatitis B virus in middle\u2010 and late\u2010stage pregnancy with high viral loads"],"prefix":"10.1002","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9091-7290","authenticated-orcid":false,"given":"Jing","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases Qilu Hospital of Shandong University  Jinan Shandong 250012 China"},{"name":"Department of Infectious Diseases The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China  Hefei Anhui 230001 China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5108-529X","authenticated-orcid":false,"given":"Lin lin","family":"Tao","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Infectious Diseases The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China  Hefei Anhui 230000 China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0983-068X","authenticated-orcid":false,"given":"Li xian","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Qilu Hospital of Shandong University,Jinan  Jinan Shandong 250012 China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,8,29]]},"reference":[{"key":"e_1_2_7_1_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra031087"},{"issue":"1","key":"e_1_2_7_1_3_1","first-page":"4","article-title":"Viral hepatitis B and hepatocellular carcinoma","volume":"74","author":"Michielsen P","year":"2017","journal-title":"Acta Gastroenterol Belg"},{"key":"e_1_2_7_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.11.011"},{"key":"e_1_2_7_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.01.019"},{"key":"e_1_2_7_1_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01492.x"},{"key":"e_1_2_7_1_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"e_1_2_7_1_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-004-0021-x"},{"key":"e_1_2_7_1_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-10-25"},{"key":"e_1_2_7_1_10_1","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2015.16.18.8665"},{"key":"e_1_2_7_1_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-014-2305-7"},{"key":"e_1_2_7_1_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12670"},{"key":"e_1_2_7_1_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-018-0847-2"},{"key":"e_1_2_7_1_14_1","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.76.s3.06"},{"key":"e_1_2_7_1_15_1","first-page":"905","article-title":"[Management and treatment of pregnant women with hepatitis B]","volume":"153","author":"Boland GJ","year":"2009","journal-title":"Ned Tijdschr Geneeskd"},{"key":"e_1_2_7_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_7_1_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28156"},{"key":"e_1_2_7_1_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"e_1_2_7_1_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12834"},{"key":"e_1_2_7_1_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.01056.x"},{"key":"e_1_2_7_1_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12834"},{"key":"e_1_2_7_1_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28156"},{"key":"e_1_2_7_1_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.10.026"},{"key":"e_1_2_7_1_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01412.x"},{"key":"e_1_2_7_1_25_1","first-page":"641","article-title":"[Telbivudine\u2010associated creatine kinase elevation in chronic hepatitis B patients]","volume":"20","author":"Ren JB","year":"2012","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"e_1_2_7_1_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.04.038"},{"key":"e_1_2_7_1_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-014-3230-3"},{"key":"e_1_2_7_1_28_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i45.6645"},{"key":"e_1_2_7_1_29_1","first-page":"47","article-title":"A deformity fetus delivered by a hepatitis B woman treated with lamivudine during pregnancy","volume":"7","author":"He Q","year":"2010","journal-title":"J US China Med Sci"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.25566","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.25566","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmv.25566","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.25566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T21:40:51Z","timestamp":1694209251000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.25566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,29]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1002\/jmv.25566"],"URL":"https:\/\/doi.org\/10.1002\/jmv.25566","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"type":"print","value":"0146-6615"},{"type":"electronic","value":"1096-9071"}],"subject":[],"published":{"date-parts":[[2019,8,29]]},"assertion":[{"value":"2019-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}